Business
GoodRx Reports Fourth Quarter and Full Year 2025 Results
Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance Pharma Direct Revenue Beats Previous Outlook with Over
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"\nFourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance\n\n\nPharma Direct Revenue Beats Previous Outlook with Over 40% Year-Over-Year Growth for 2025\n\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGoodRx Holdings, Inc. (Nasdaq: GDRX) (\"we,\" \"us,\" \"our,\" “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the fourth quarter and full year of 2025.\n\n\nFourth Quarter 2025 Highlights\n\n\n\nRevenue of $194.8 million\n\n\n\nNet income of $5.4 million; Net income margin of 2.8%\n\n\n\nAdjusted Net Income1 of $29.0 million; Adjusted Net Income Margin1 of 14.9%\n\n\n\nAdjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.4%\n\n\n\nNet cash provided by operating activities of $32.9 million\n\n\n\nFull Year 2025 Highlights\n\n\n\nRevenue of $796.9 million\n\n\n\nNet income of $30.4 million; Net income margin of 3.8%\n\n\n\nAdjusted Net Income1 of $126.1 million; Adjusted Net Income Margin1 of 15.8%\n\n\n\nAdjusted EBITDA1 of $270.5 million; Adjusted EBITDA Margin1 of 33.9%\n\n\n\nNet cash provided by operating activities of $167.9 million\n\n\n\n“We delivered a strong finish to the year by executing across our key priorities, expanding manufacturer partnerships, growing differentiated subscription offerings, and strengthening retail relationships,” said Wendy Barnes, President and Chief Executive Officer of GoodRx. “We rebranded Pharma Manufacturer Solutions as Pharma Direct and are continuing to elevate it as a key growth driver of our business, reflecting our belief that self-pay and direct-to-consumer engagement will define the future of prescription access. We are confident that the actions we’re taking today position us to return to growth beyond 2026, expand our role across the healthcare ecosystem, and create meaningful long-term value for consumers, partners, and stockholders.”\n\n\n\n\n1\n\n\n\n\n\n\nAdjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for...